NCT04823208 is a Phase 1 clinical trial of LY3437943 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company.

Who is sponsoring NCT04823208?

NCT04823208 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT04823208?

Interventions in NCT04823208: LY3437943, Placebo.

What condition does NCT04823208 study?

NCT04823208 studies Diabetes Mellitus, Type 2.

Is NCT04823208 still recruiting?

NCT04823208 is currently completed. Last updated 22 August 2022.

Last reviewed 2022-08-22 · How we verify

NCT04823208

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

Completed Phase 1 Last updated 22 August 2022

What this trial tests

Phase 1 trial testing LY3437943 in Diabetes Mellitus, Type 2 in 64 participants. Completed in 23 June 2022.

Timeline

24 May 2021

Primary endpoint
23 June 2022

23 June 2022

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	64
Start date	24 May 2021
Primary completion	23 June 2022
Estimated completion	23 June 2022
Sites	4 locations across Japan

Drugs / interventions tested

LY3437943 — full drug profile →
Placebo

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 20 to 70, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to learn about the side effects of LY3437943 when given to Japanese participants with type 2 diabetes mellitus. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last up to 5 months, inclusive of screening and will include 16 visits to the study center.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, et al · · 2022 · cited 245× · PMID 36031641 · DOI 10.1038/s41392-022-01149-x
Transforming obesity: The advancement of multi-receptor drugs.
Kusminski CM, Perez-Tilve D, Müller TD, DiMarchi RD, et al · · 2024 · cited 77× · PMID 39059360 · DOI 10.1016/j.cell.2024.06.003

Verify or expand the search:

Other trials of LY3437943

Trials testing the same drug.

NCT06313528 — A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 · Phase 1 · completed
NCT06039826 — A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese · Phase 1 · completed
NCT06003465 — A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices · Phase 1 · completed
NCT05959096 — A Study of LY3437943 in Healthy Participants With a High Body Mass Index · Phase 1 · completed
NCT05916560 — A Study of LY3437943 in Participants With Impaired and Normal Liver Function · Phase 1 · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04823208 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 22 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04823208.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing